Small RNA combination therapy for lung cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 34, 2014, Pages

  Xue, Wen ^a   Dahlman, James E ^a,c   Tammela, Tuomas ^a   Khan, Omar F ^a,b   Sood, Sabina ^a   Dave, Apeksha ^a   Cai, Wenxin ^a   Chirino, Leilani M ^a   Yang, Gillian R ^a   Bronson, Roderick ^d   Crowley, Denise G ^a   Sahay, Gaurav ^a   Schroeder, Avi ^a,e   Langer, Robert ^a,b,c   Anderson, Daniel G ^a,b,c   Jacks, Tyler ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^d TUFTS UNIVERSITY   (United States)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

miR 34; Nanotechnology

Indexed keywords

CISPLATIN; MICRORNA 34A; MITOGEN ACTIVATED PROTEIN KINASE; NANOPARTICLE; PROTEIN P53; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; KRAS2 PROTEIN, MOUSE; MICRORNA; MIRN34 MICRORNA, MOUSE; ONCOPROTEIN; PROTEIN P21; RAS PROTEIN; RNA;

ADENOCARCINOMA CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE TARGETING; GENETICALLY ENGINEERED MOUSE STRAIN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIRSTEN SARCOMA ONCOVIRUS; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; DEFICIENCY; GENETICS; HUMAN; KNOCKOUT MOUSE; LUNG NEOPLASMS; METABOLISM; MULTIMODALITY CANCER THERAPY; MUTATION; NANOTECHNOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; COMBINED MODALITY THERAPY; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICRORNAS; MUTATION; NANOPARTICLES; NANOTECHNOLOGY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; RNA, NEOPLASM; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84906706945     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1412686111     Document Type: Article

References (54)

1. Ambros V (2008) The evolution of our thinking about microRNAs. Nat Med 14(10):1036-1040.
2. Mendell JT, Olson EN (2012) MicroRNAs in stress signaling and human disease. Cell 148(6):1172-1187.
3. Ventura A, Jacks T (2009) MicroRNAs and cancer: Short RNAs go a long way. Cell 136(4):586-591.
4. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10(10):704-714.
5. Kasinski AL, Slack FJ (2011) Epigenetics and genetics. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 11(12):849-864.
6. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK (2011) RNA interference in the clinic: Challenges and future directions. Nat Rev Cancer 11(1):59-67.
7. Bumcrot D, Manoharan M, Koteliansky V, Sah DW (2006) RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat Chem Biol 2(12):711-719. (Pubitemid 44764213)
8. Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG (2012) Action and reaction: The biological response to siRNA and its delivery vehicles. Mol Ther 20(3):513-524.
9. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov 8(2):129-138.
10. Schroeder A, et al. (2012) Treating metastatic cancer with nanotechnology. Nat Rev Cancer 12(1):39-50.
11. Kota J, et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6):1005-1017.
12. Kasinski AL, Slack FJ (2012) miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 72(21):5576-5587.
13. Kanasty R, Dorkin JR, Vegas A, Anderson D (2013) Delivery materials for siRNA therapeutics. Nat Mater 12(11):967-977.
14. Ren Y, et al. (2012) Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med 4(147):147ra112.
15. Yao YD, et al. (2012) Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med 4(130):130ra148.
16. Huang YH, et al. (2009) Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc Natl Acad Sci USA 106(9):3426-3430.
17. Trang P, et al. (2011) Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19(6):1116-1122.
18. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367-1380.
19. DuPage M, Dooley AL, Jacks T (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4(7):1064-1072.
20. Engelman JA, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14(12):1351-1356.
21. Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M (2012) MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Res 72(12):3048-3059.
22. Xue W, et al. (2011) Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov 1(3):236-247.
23. De Raedt T, et al. (2011) Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 20(3):400-413.
24. Chen Z, et al. (2012) A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483(7391):613-617.
25. Oliver TG, et al. (2010) Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 24(8):837-852.
26. Heist RS, Engelman JA (2012) SnapShot: Non-small cell lung cancer. Cancer Cell 21(3):448-e442.
27. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D (2011) RAS oncogenes: Weaving a tumorigenic web. Nat Rev Cancer 11(11):761-774.
28. Chin L, et al. (1999) Essential role for oncogenic Ras in tumour maintenance. Nature 400(6743):468-472. (Pubitemid 29361802)
29. Fisher GH, et al. (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15(24):3249-3262. (Pubitemid 34008191)
30. Jechlinger M, Podsypanina K, Varmus H (2009) Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction. Genes Dev 23(14):1677-1688.
31. Feldser DM, et al. (2010) Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468(7323):572-575.
32. Levine AJ, Oren M (2009) The first 30 years of p53: Growing ever more complex. Nat Rev Cancer 9(10):749- 758.
33. Junttila MR, et al. (2010) Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468(7323):567-571.
34. He L, He X, Lowe SW, Hannon GJ (2007) microRNAs join the p53 network - Another piece in the tumour-suppression puzzle. Nat Rev Cancer 7(11):819- 822.
35. Hermeking H (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17(2):193-199.
36. Hermeking H (2012) MicroRNAs in the p53 network: Micromanagement of tumour suppression. Nat Rev Cancer 12(9):613-626.
37. He L, et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature 447(7148):1130-1134. (Pubitemid 47014436)
38. He X, He L, Hannon GJ (2007) The guardian's little helper: MicroRNAs in the p53 tumor suppressor network. Cancer Res 67(23):11099-11101. (Pubitemid 350248530)
39. Bader AG (2012) miR-34-A microRNA replacement therapy is headed to the clinic. Front Genet 3:120.
40. Peer D, et al. (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751-760. (Pubitemid 350223348)
41. Semple SC, et al. (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28(2):172-176.
42. Love KT, et al. (2010) Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107(5):1864-1869.
43. Tabernero J, et al. (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3(4):406-417.
44. Davis ME, et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291):1067-1070.
45. Dahlman JE, et al. (2014) In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat Nanotechnol, 10.1038/nnano.2014.84.
46. Madisen L, et al. (2010) A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci 13(1):133-140.
47. Cheung AF, Dupage MJ, Dong HK, Chen J, Jacks T (2008) Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res 68(22):9459-9468.
48. Whitehead K, Dahlman JE, Langer RS, Anderson DG (2010) Silencing or stimulation? siRNA delivery and the immune system. Annu Rev Chem Biomol Eng 2:77-96.
49. Robbins M, Judge A, MacLachlan I (2009) siRNA and innate immunity. Oligonucleotides 19(2):89-102.
50. Zorde Khvalevsky E, et al. (2013) Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci USA 110(51):20723-20728.
51. Nishimura M, et al. (2013) Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov 3(11):1302-1315.
52. Engelman JA, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039-1043. (Pubitemid 46799492)
53. Chen D, et al. (2012) Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc 134(16):6948-6951.
54. Tammela T, et al. (2011) VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol 13(10):1202-1213.